Six-month treatment of obesity with sibutramine 15 mg; A double-blind, placebo-controlled monocenter clinical trial in a hispanic population

Obesity Research

Volumn 8, Issue 1, 2000, Pages 71-82

  Martínez Cuellar, Guillermina Elisa ^a   Martínez Ruiz, Alberto ^b   Revilla Monsalve, Maria Cristina ^c   Berber, Arturo ^d  

^a Modulo Diabet Hosp Psiquiatrico U   (Mexico)

^b Presidente Comite Loc Investigacion   (Mexico)

^c INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^d BASF Mexicana SA de CV   (Mexico)

Author keywords

Clinical trial; Hispanic population; Obesity treatment; Placebo controlled; Sibutramine

Indexed keywords

ANOREXIGENIC AGENT; CYCLOBUTANE DERIVATIVE; PLACEBO; SIBUTRAMINE;

ADOLESCENT; ADULT; AGED; ARTICLE; BODY CONSTITUTION; BODY MASS; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HISPANIC; HUMAN; MALE; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; APPETITE DEPRESSANTS; BODY CONSTITUTION; BODY MASS INDEX; CARDIOVASCULAR SYSTEM; CYCLOBUTANES; DOUBLE-BLIND METHOD; FEMALE; HISPANIC AMERICANS; HUMANS; MALE; MIDDLE AGED; OBESITY; PLACEBOS; PROSPECTIVE STUDIES; WEIGHT LOSS;

EID: 0033632002     PISSN: 10717323     EISSN: None     Source Type: Journal    
DOI: 10.1038/oby.2000.10     Document Type: Article

References (32)

1. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA. 1994;272:205-11.
2. Flegal KM, Carrol MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes. 1998;22:39-47.
3. Harris MI, Flegal KM, Cowie CC, et al. Prevalence of diabetes, impaired fasting glucose and impaired glucose tolerance in U.S. adults. Diabetes Care. 1998;21:518-24.
4. Sorel JE, Ragland DR, Syme SL. Blood pressure in Mexican-Americans, whites and blacks. The second National Health and Nutrition Examination Survey and the Hispanic Health and Nutrition Examination Survey. Am J Epidemiol. 1991;134:370-8.
5. Gillum RF. Epidemiology of stroke in Hispanic Americans. Stroke. 1995;26:1707-12.
6. Harris-Hooker S, Sanford GL. Lipids and lipoproteins and coronary heart disease in minority populations. Atherosclerosis. 1994;108(Suppl):S83-S104.
7. Váldez R, González-Villalpando C, Mitchell BD, Haffner SM, Stern MP. Differential impact of obesity in related populations. Obes Res. 1995;3(Suppl 2):223s-32s.
8. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obes. 1997;21(Suppl 1):S25-S29.
9. Heal DJ, Cheetham SC. The pharmacology of sibutramine, the first serotonin and noradrenaline reuptake inhibitor to be developed for the treatment of obesity. La Lettre du Pharmacologue. 1997;11(Suppl 10):3-8.
10. Rolls BJ, Shide DJ, Thorwart ML, Ulbrecht JS. Sibutramine reduces food intake in non-dieting women with obesity. Obes Res. 1998;6:1-11.
11. Seagle HM, Bessesen DH, Hill JO. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes Res. 1998;6:115-21.
12. Wauters M, Van Gaal L, Peiffer F, Gubbels N, Van de Sompel A, Mertens I, De Leeuw I. Sibutramine may limit decrease in resting metabolic rate during weight loss. Obes Res. 1997;5(Suppl 1):41S.
13. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. Thermogenic effects of sibutramine in humans. Am J Clin Nutr. 1998;68:1180-6.
14. Bray GA, Ryan DH, Gordon D, Heidingfelder S, Cerise F, Wilson K. A double-blind randomized placebo-controlled trial of sibutramine. Obes Res. 1996;4:263-70.
15. Glantz SA, ed. What Does "Not Significant" Really Mean? Primer of Biostatistics. 3rd edition. New York: McGraw-Hill Inc; 1992;155-87.
16. Casillas LE, Vargas LA. Height and weight charts for Mexican adults. Arch Invest Med (Mex). 1980;11:157-74.
17. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA. 1996;276:1907-15.
18. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther. 1996;18:1006-36.
19. Stern JS, Hirsch J, Blair SN, et al. Weighing the options: criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res. 1995; 3:591-604.
20. Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study. Int J Obes Relat Metab Disord. 1998;22: 32-38.
21. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7: 189-98.
22. Smith IG. Long-term weight loss with sibutramine (Meridia): a once-daily serotonin and norepinephrine reuptake inhibitor. Obes Res. 1997;5(Suppl 1):80S.
23. Stern MP, González C, Mitchell BD, Villalpando E, Haffner SM, Hazuda HP. Genetic and environmental determinants of type II diabetes in Mexico City and San Antonio. Diabetes. 1992;41:484-92.
24. McCarty MF. Insulin resistance in Mexican Americans: a precursor to obesity and diabetes. Med Hypotheses. 1993;41: 308-15.
25. Stern MP, González C, Hernandex M, et al. Performance of semiquantitative food frequency questionnaires in international comparisons. Mexico City versus San Antonio, Texas. Ann Epidemiol. 1993;3:300-7.
26. Haffner SM, González Villalpando C, Hazuda HP, Váldez R, Mykkanen L, Stern MP. Prevalence of hypertension in Mexico City and San Antonio, Texas. Circulation. 1994;90: 1542-9.
27. Escobedo-de-la-Peña J, Islas S, Lifshitz-Guizberg A, Méndez JD, Revilla C, Vázquez-Estupiñan F. Higher prevalence of diabetes in hypertensive subjects with upper body fat distribution. Rev Invest Clin. 1998;50:5-12.
28. Fanghänel-Salmon G, Sánchez-Reyes L, Arellano-Montano S, Váldes-Liaz E, Chavira-López J, Rascón-Pacheco RA. The prevalence of risk factors for coronary disease in workers of the Hospital General de Mexico. Salud Pública Mex. 1997;39:427-32.
29. Lean MEJ. Sibutramine: a review of clinical efficacy. Int J Obes. 1997;21(Suppl 1):S30-S6.
30. Astrup A. Clinical pharmacology of sibutramine. La Lettre du Pharmacologue. 1997;11(Suppl 10):14-6.
31. McNeely W, Goa KL. Sibutramine: a review of its contribution to the management of obesity. Drugs. 1998;56:1093-124.
32. Bray GA. Evaluation of drugs for treating obesity. Obes Res. 1995;3(Suppl 4):425S-34S.